Infusion stakeholders seek regulation of 'hangover clinics'

ALEXANDRIA, Va. – The National Home Infusion Association and several allied organizations have asked the U.S. Food and Drug Administration and state regulatory agencies to investigate unregulated, direct access infusion businesses that provide individuals with intravenous solutions absent the recommendation of a licensed prescriber.  

These businesses, they say, treat hangovers, exercise recovery and elevation sickness, which can usually be resolved with oral medications or through other means—making infusion treatment unnecessary. 

The result is the diversion of scarce resources—many of which appear on the FDA’s drug shortage list—from patients who have legitimate medical needs.  

“As organizations invested in the safe and effective administration of infused medications to patients with acute and chronic medical conditions, we are highly devoted to ensuring the availability of these products and their safe administration to patients with legitimate medical needs,” said Connie Sullivan, BSPharm, NHIA’s president and CEO. “In addition, as health care professionals, we approach patient care with the imperative to first do no harm. Unlicensed and unregulated businesses administering medically unnecessary therapies with no adherence to industry and professional standards introduces unwarranted risks. We urge state regulatory agencies and the FDA to assess the impact of these operations and establish an appropriate licensing requirement.”  

To ensure safety and address critical shortages of medical products, NHIA, American Society of Health-System Pharmacists (ASHP), National Association for Home Care and Hospice, American Society for Parenteral and Enteral Nutrition, National Infusion Center Association, and Infusion Nurses Society recommend the following: 

• Investigate and assess the extent to which direct access infusion businesses are contributing to the ongoing national shortages of parenteral drugs, nutrition components and diluents/solutions. 
• Require all businesses that sell direct access infusion therapies to the general public to comply with licensure and regulations applicable to the services offered. 
• Investigate claims of health benefit, treatment or cure, and require businesses that sell direct access infusion therapies to disclose the lack of evidence and unique risks of administering compounded IV products that are not medically necessary. 
• Establish a licensure category for businesses that sell direct access infusions.